1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update

Summary

Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation either by a home care professional or family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL), both for the patients and their caretakers. With rapidly accelerating worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide temporary improvement of symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area opportunity exists for the development of an effective pharmacologic approach.

Highlights

Key Questions Answered

- What are the preferred therapies for each country?
- The developmental pipeline consists of disease-modifying therapies (DMTs) that aim to prevent the disease in early- and presymptomatic patients. Which of these DMTs will attain high sales revenues during 2013-2023, and in which markets?
- Will amyloid-based therapies face adoption challenges in the market? What is the projected uptake of new passive immunotherapies and BACE inhibitors over the forecast period?
- How large an impact will Lundbeck’s LuAE-58054 and Forum/Mitsubishi Tanabe’s EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?
- What are the unique challenges in AD, and how will they affect the growth of the market globally?

Key Findings

- Guidelines are not closely followed due to the heterogeneity of symptoms.
- There is a widespread reluctance to seek treatment in the absence of curative therapies.
- Diagnosis in early stages of the disease remains a challenge and will affect the growth of the market over the 2013-2023 forecast period.
- Poor consensus over clinical trial endpoints required for approval.
- Symptoms related to AD require better treatment options.
- Amyloid beta is the focus of the late-stage pipeline.
- Disease-modifying therapies such as passive immunotherapies and BACE inhibitors will revitalize the AD market.

Scope

- Overview of AD and mild cognitive impairment (MCI), including etiology, general symptoms, country-specific compliance/caregiving data and epidemiology.
- Annualized AD market revenue, annual cost of treatment and usage patterns from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, unmet needs, clinical trial mapping and implications for the AD market.
- Pipeline analysis: comprehensive data split across AD disease severities for disease-modifying and symptomatic therapies with novel mechanisms of action in AD, including Lilly’s solanezumab, Biogen’s aducanumab, Roche’s gantenerumab and crenezumab (Phase II). Merck & Co.’s M-8931, and Lilly/AstraZeneca’s AZD-3293.
- Analysis of the current and future market competition in the global AD drug market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most competitive pipelines.
- Develop business strategies by understanding the trends shaping and driving the AD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global AD market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Disease Staging Systems 38
3.3 Symptoms 41
3.4 Prognosis 43
3.5 Quality of Life 43
4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and Comorbidities 46
4.2.1 A family history of Alzheimer's increases the risk of developing the disease by 7.5 times 47
4.2.2 The APOE ?4 allele triples the risk for AD 48
4.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life 48
4.2.4 The incidence and prevalence of AD double every five years after age 65 years 49
4.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women 49
4.2.6 Women are 1.5 times more likely to develop AD than men 50
4.2.7 Depression triples the risk for AD, and is the most common comorbidity 50
4.2.8 Up to 70% of AD patients also suffer from anxiety 51
4.2.9 Psychosis and agitation are common comorbidities in Alzheimer's patients 51
4.3 Global Trends 51
4.3.1 US 52
4.3.2 5EU 53
4.3.3 Japan 55
4.3.4 China 56
4.3.5 India 56
4.4 Forecast Methodology 57
4.4.1 Sources Used 62
4.4.2 Forecast Assumptions and Methods 69
4.4.3 Sources Not Used 79
4.5 Epidemiology Forecast (2013-2023) 81
4.5.1 Total Prevalent Cases of AD 81
4.5.2 Age-Specific Total Prevalent Cases of AD 83
4.5.3 Sex-Specific Total Prevalent Cases of AD 85
4.5.4 Age-Standardized Total Prevalence of AD 88
4.5.5 Total Prevalent Cases of AD, by Severity 89
4.5.6 Total Prevalent Cases of MCI 91
4.5.7 Age-Specific Total Prevalent Cases of MCI 93
4.5.8 Sex-Specific Total Prevalent Cases of MCI 95
4.5.9 Age-Standardized Total Prevalence of MCI 98
4.6 Discussion 99
4.6.1 Conclusions Regarding the Epidemiological Trends 99
4.6.2 Limitations of the Analysis 101
4.6.3 Strengths of the Analysis 102
5 Disease Management 103
5.1 Diagnosis Overview 103
5.1.1 Probable AD Dementia 106
5.1.2 Preclinical AD 107
5.1.3 MCI 108
5.2 Treatment Overview 110
5.3 Clinical Practice 112
5.3.1 Leading Prescribed Therapies 114
5.4 US 115
5.5 France 118
5.6 Germany 120
5.7 Italy 122
5.8 Spain 124
5.9 UK 126
5.10 Japan 129
5.11 China 131
5.12 India 133
6 Competitive Assessment 135
6.1 Overview 135
6.2 Product Profiles - Major Brands 136
6.2.1 Aricept (donepezil hydrochloride) 136
6.2.2 Exelon (rivastigmine, rivastigmine tartrate) 141
6.2.3 Razadyne (galantamine hydrobromide) 146
6.2.4 Namenda (memantine hydrochloride) 151
6.3 Other Drugs/Classes 157
7 Unmet Need and Opportunity 159
7.1 Overview 159
7.2 Drugs with Disease-Modifying Mechanisms of Action 160
7.2.1 Unmet Need 160
7.2.2 Gap Analysis 161
7.2.3 Opportunity 162
7.3 Diagnosis in the Prodromal or Presymptomatic Stages 163
7.3.1 Unmet Need 163
7.3.2 Gap Analysis 164
7.3.3 Opportunity 165
7.4 Improved Control of Symptoms 166
7.4.1 Unmet Need 166
7.4.2 Gap Analysis 167
7.4.3 Opportunity 168
7.5 Easier Access to Treatment 169
7.5.1 Unmet Need 169
7.5.2 Gap Analysis 169
7.5.3 Opportunity 170
8 Pipeline Assessment 172
8.1 Overview 172
8.2 Clinical Trial Mapping 173
8.2.1 Clinical Trials by Class 173
8.3 Promising Drugs in Clinical Development 174
8.3.1 Biopharmaceutical Products 176
8.3.2 Small Molecule 209
8.3.3 Other Drugs in Development 258
9 Current and Future Players 260
9.1 Overview 260
9.2 Trends in Corporate Strategy 261
9.3 Company Profiles 262
9.3.1 Actavis 262
9.3.2 Lundbeck 265
9.3.3 Eisai 268
9.3.4 Pfizer 270
9.3.5 Novartis 272
9.3.6 Roche 274
9.3.7 Eli Lilly 276
9.3.8 Merck and Co. 280
9.3.9 AstraZeneca 281
9.3.10 Takeda 283
10 Market Outlook 286
10.1 Global Markets 286
10.1.1 Forecast 286
10.1.2 Drivers and Barriers - Global Issues 294
10.2 United States 297
10.2.1 Forecast 297
10.2.2 Key Events 301
10.2.3 Drivers and Barriers 302
10.3 France 305
10.3.1 Forecast 305
10.3.2 Key Events 308
10.3.3 Drivers and Barriers 309
10.4 Germany 312
10.4.1 Forecast 312
10.4.2 Key Events 315
10.4.3 Drivers and Barriers 315
10.5 Italy 317
10.5.1 Forecast 317
10.5.2 Key Events 321
10.5.3 Drivers and Barriers 321
10.6 Spain 323
10.6.1 Forecast 323
10.6.2 Key Events 327
10.6.3 Drivers and Barriers 327
10.7 United Kingdom 329
10.7.1 Forecast 329
10.7.2 Key Events 332
10.7.3 Drivers and Barriers 333
10.8 Japan 335
10.8.1 Forecast 335
10.8.2 Key Events 339
10.8.3 Drivers and Barriers 339
10.9 China 341
10.9.1 Forecast 341
10.9.2 Key Events 345
10.9.3 Drivers and Barriers 345
10.10 India 347
10.10.1 Forecast 347
10.10.2 Key Events 350
10.10.3 Drivers and Barriers 350
11 Appendix 353
11.1 Bibliography 353
11.2 Abbreviations 378
11.3 Methodology 388
11.4 Forecasting Methodology 388
11.4.1 Diagnosed AD Patients 388
11.4.2 Percent Drug-Treated Patients 389
11.4.3 Drugs Included in Each Therapeutic Class 389
11.4.4 Launch and Patent Expiry Dates 390
11.4.5 General Pricing Assumptions 391
11.4.6 Compliance Assumptions 392
11.4.7 Individual Drug Assumptions 394
11.4.8 Generic Erosion 400
11.4.9 Pricing of Pipeline Agents 400
11.5 Primary Research - KOLs Interviewed for This Report 402
11.6 Primary Research - Prescriber Survey 403
11.7 About the Authors 404
11.7.1 Analyst 404
11.7.2 Therapy Area Director 404
11.7.3 Epidemiologist 405
11.7.4 Global Head of Healthcare 405
11.8 About GlobalData 406
11.9 Disclaimer 406

1.1 List of Tables
Table 1: Three-Stage Classification of AD 39
Table 2: Seven-Stage Reisberg Scale 40
Table 3: Common Symptoms of AD 42
Table 4: Risk Factors and Comorbidities for AD 47
Table 5: DSM-III-R Criteria for the Diagnosis of Dementia 57
Table 6: NINCDS-ADRDA Criteria for the Diagnosis of AD 58
Table 7: 9MM, Epidemiological Sources for AD Total Prevalence Data 59
Table 8: 9MM, Epidemiological Sources for AD Total Prevalence Data, Based on Severity 60
Table 9: 9MM, Epidemiological Sources for MCI Total Prevalence Data 61
Table 10: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of AD 80
Table 11: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of MCI 80
Table 12: 9MM, Total Prevalent Cases of AD, Ages ?60 Years, Men and Women, N, 2013-2023 82
Table 13: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N (Row %), 2013 84
Table 14: 9MM, Total Prevalent Cases of AD, by Sex, Age ? 60 Years, N (Row %), 2013 86
Table 15: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N (Row %), 2013 90
Table 16: 9MM, Total Prevalent Cases of MCI, Ages ?60 Years, Men and Women, N, 2013-2023 92
Table 17: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N (Row %), 2013 94
Table 18: 9MM, Total Prevalent Cases of MCI, by Sex, Age ?60 Years, N (Row %), 2013 96
Table 19: Common Used Diagnostic Guidelines for AD 104
Table 20: DSM-IV-TR Diagnostic Criteria for AD 105
Table 21: Summary of NINCDS-ADRDA Diagnostic Criteria for AD 105
Table 22: Proposed NIA-AA Staging Classification for Preclinical AD 108
Table 23: NIA-AA Biomarker Criteria for MCI 110
Table 24: Commonly Used Treatment Guidelines for AD 112
Table 25: Most Prescribed Drugs for AD by Class in the 9MM, 2013 114
Table 26: Most Commonly Prescribed Off-label Drug Classes for AD in the 9MM, 2013 115
Table 27: AD Market Country Profile - US 117
Table 28: AD Market Country Profile - France 119
Table 29: AD Market Country Profile - Germany 121
Table 30: AD Market Country Profile - Italy 123
Table 31: AD Market Country Profile - Spain 125
Table 32: AD Market Country Profile - UK 128
Table 33: AD Market Country Profile - Japan 130
Table 34: AD Market Country Profile - China 132
Table 35: AD Market Country Profile - India 134
Table 36: Leading Therapies in AD, 2013 136
Table 37: Product Profile - Aricept 137
Table 38: Aricept SWOT Analysis, 2013 140
Table 39: Global Sales Forecasts ($m) for Aricept, 2013-2023 141
Table 40: Product Profile - Exelon 142
Table 41: Exelon SWOT Analysis, 2013 145
Table 42: Global Sales Forecasts ($m) for Exelon, 2013-2023 146
Table 43: Product Profile - Razadyne 147
Table 44: Razadyne SWOT Analysis, 2013 150
Table 45: Global Sales Forecasts ($m) for Razadyne, 2013-2023 151
Table 46: Product Profile - Namenda 153
Table 47: Namenda SWOT Analysis, 2013 156
Table 48: Global Sales Forecasts ($m) for Namenda, 2013-2023 157
Table 49: Summary of Other Therapeutic Classes for AD, 2013 158
Table 50: Unmet Need and Opportunity in the AD Market 160
Table 51: Pre-Registration and Phase III Pipeline in AD/MCI, September 2014 174
Table 52: Comparison of Therapeutic Classes in Development for AD 176
Table 53: Product Profile - Solanezumab 177
Table 54: Efficacy Outcomes in EXPEDITION 1, ITT 178
Table 55: Efficacy Outcomes in EXPEDITION 2, ITT 179
Table 56: Outcomes in Mild and Moderate AD Patients in EXPEDITION 1 and 2, ITT 180
Table 57: Summary of Adverse Events in EXPEDITION 1 and EXPEDITION 2 181
Table 58: Solanezumab SWOT Analysis, 2014 184
Table 59: Global Sales Forecasts ($m) for Solanezumab, 2013-2023 185
Table 60: Product Profile - Gantenerumab 186
Table 61: Gantenerumab SWOT Analysis, 2014 190
Table 62: Global Sales Forecasts ($m) for Gantenerumab, 2013-2023 191
Table 63: Product Profile - Crenezumab 192
Table 64: Crenezumab SWOT Analysis, 2014 194
Table 65: Global Sales Forecasts ($m) for Crenezumab, 2013-2023 195
Table 66: Product Profile - Aducanumab 197
Table 67: Mean Change in Composite SUVR from Baseline to Week 26 and Week 54 198
Table 68: Aducanumab SWOT Analysis, 2015 203
Table 69: Global Sales Forecasts ($m) for Aducanumab, 2013-2023 204
Table 70: Product Profile - Flebogamma + Albutein 205
Table 71: Flebogamma + Albutein SWOT Analysis, 2014 208
Table 72: Global Sales Forecasts ($m) for Flebogamma + Albutein, 2013-2023 209
Table 73: Product Profile - Namzaric 210
Table 74: Safety of Namenda in Combination with Aricept 211
Table 75: Namzaric SWOT Analysis, 2014 213
Table 76: Global Sales Forecasts ($m) for Namzaric, 2013-2023 214
Table 77: Product Profile - MK-8931 215
Table 78: MK-8931 SWOT Analysis, 2014 218
Table 79: Global Sales Forecasts ($m) for MK-8931, 2013-2023 219
Table 80: Product Profile - AZD-3293 220
Table 81: AZD-3293 SWOT Analysis, 2014 223
Table 82: Global Sales Forecasts ($m) for AZD-3293, 2013-2023 224
Table 83: Product Profile - TTP-488 225
Table 84: Changes from Baseline in the ADAS-Cog Score 226
Table 85: TTP-488 SWOT Analysis, 2014 228
Table 86: Global Sales Forecasts ($m) for TTP-488, 2013-2023 229
Table 87: Product Profile - TRx-0237 230
Table 88: TRx-0237 SWOT Analysis, 2014 232
Table 89: Global Sales Forecasts ($m) for TRx-0237, 2013-2023 233
Table 90: Product Profile - AB-1010 234
Table 91: Efficacy of AB-1010, as Measured by the ADAS-Cog at Week 24 235
Table 92: Frequency of Adverse Events, AB-1010 Versus Placebo 236
Table 93: AB-1010 SWOT Analysis, 2014 237
Table 94: Global Sales Forecasts ($m) for AB-1010, 2013-2023 238
Table 95: Product Profile - AD-4833 239
Table 96: Common Adverse Events with AD-4833 Versus Placebo 241
Table 97: AD-4833 SWOT Analysis, 2014 242
Table 98: Global Sales Forecasts ($m) for AD-4833, 2013-2023 243
Table 99: Product Profile - EVP-6124 244
Table 100: Treatment-Emergent Adverse Events Observed With EVP-6124 Versus Placebo 246
Table 101: EVP-6124 SWOT Analysis, 2014 247
Table 102: Global Sales Forecasts ($m) for EVP-6124, 2013-2023 248
Table 103: Product Profile - LuAE-58054 249
Table 104: LuAE-58054 SWOT Analysis, 2014 252
Table 105: Global Sales Forecasts ($m) for LuAE-58054, 2013-2023 253
Table 106: Product Profile - ARC-029 254
Table 107: ARC-029 SWOT Analysis, 2014 257
Table 108: Global Sales Forecasts ($m) for ARC-029, 2013-2023 258
Table 109: Drugs in Development, 2014 259
Table 110: Actavis' AD Portfolio Assessment, 2014 263
Table 111: Lundbeck's AD Portfolio Assessment, 2014 266
Table 112: Eisai's AD Portfolio Assessment, 2014 269
Table 113: Pfizer's AD Portfolio Assessment, 2014 271
Table 114: Novartis' AD Portfolio Assessment, 2014 273
Table 115: Roche's AD Portfolio Assessment, 2014 275
Table 116: Eli Lilly's AD Portfolio Assessment, 2014 278
Table 117: Merck's AD Portfolio Assessment, 2014 280
Table 118: AstraZeneca's AD Portfolio Assessment, 2014 282
Table 119: Takeda's AD Portfolio Assessment, 2014 285
Table 120: Global Sales Forecasts ($m) for AD, 2013-2023 289
Table 121: Global AD Market - Drivers and Barriers, 2013-2023 294
Table 122: Sales Forecasts ($m) for AD in the US, 2013-2023 299
Table 123: Key Events Impacting Sales for AD in the US, 2013-2023 301
Table 124: AD Market - Drivers and Barriers in the US, 2013-2023 302
Table 125: Sales Forecasts ($m) for AD in France, 2013-2023 306
Table 126: Key Events Impacting Sales for AD in France, 2013-2023 308
Table 127: AD Market - Drivers and Barriers in France, 2013-2023 309
Table 128: Sales Forecasts ($m) for AD in Germany, 2013-2023 313
Table 129: Key Events Impacting Sales for AD in Germany, 2013-2023 315
Table 130: AD Market - Drivers and Barriers in Germany, 2013-2023 315
Table 131: Sales Forecasts ($m) for AD in Italy, 2013-2023 319
Table 132: Key Events Impacting Sales for AD in Italy, 2013-2023 321
Table 133: AD Market - Drivers and Barriers in Italy, 2013-2023 321
Table 134: Sales Forecasts ($m) for AD in Spain, 2013-2023 325
Table 135: Key Events Impacting Sales for AD in Spain, 2013-2023 327
Table 136: AD Market - Drivers and Barriers in Spain, 2013-2023 327
Table 137: Sales Forecasts ($m) for AD in the UK, 2013-2023 330
Table 138: Key Events Impacting Sales for AD in the UK, 2013-2023 332
Table 139: AD Market - Drivers and Barriers in the UK, 2013-2023 333
Table 140: Sales Forecasts ($m) for AD in Japan, 2013-2023 337
Table 141: Key Events Impacting Sales for AD in Japan, 2013-2023 339
Table 142: AD Market - Drivers and Barriers in Japan, 2013-2023 339
Table 143: Sales Forecasts ($m) for AD in China, 2013-2023 343
Table 144: Key Events Impacting Sales for AD in China, 2013-2023 345
Table 145: AD Market - Drivers and Barriers in China, 2013-2023 345
Table 146: Sales Forecasts ($m) for AD in India, 2013-2023 348
Table 147: Key Events Impacting Sales for AD in India, 2013?2023 350
Table 148: AD Market - Drivers and Barriers in India, 2013-2023 350
Table 149: Key Launch Dates, Marketed and Pipeline AD Products 390
Table 150: Key Patent Expirations, Marketed and Pipeline AD Products 391
Table 151: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 403

1.2 List of Figures
Figure 1: AD Biomarker Tests by Pathophysiology 35
Figure 2: Dynamic Changes in AD Biomarkers Over Time 36
Figure 3: 9MM, Total Prevalent Cases of AD, Ages ?60 Years, Men and Women, N, 2013-2023 83
Figure 4: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N, 2013 85
Figure 5: 9MM, Total Prevalent Cases of AD, by Sex, Age ?60 Years, N, 2013 87
Figure 6: 9MM, Age-Standardized Total Prevalence of AD, Age ?60 Years, Men and Women, %, 2013 89
Figure 7: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N, 2013 91
Figure 8: 9MM, Total Prevalent Cases of MCI, Ages ?60 Years, Men and Women, N, 2013-2023 93
Figure 9: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N, 2013 95
Figure 10: 9MM, Total Prevalent Cases of MCI, by Sex, Age ?60 Years, N, 2013 97
Figure 11: 9MM, Age-Standardized Total Prevalence of MCI, Age ?60 Years, Men and Women, %, 2013 99
Figure 12: Disease Management Timeline for AD 113
Figure 13: Active AD Clinical Trials by Drug Target, September 2014 173
Figure 14: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2013-2023 175
Figure 15: Clinical and Commercial Positioning of Solanezumab 183
Figure 16: Clinical and Commercial Positioning of Gantenerumab 189
Figure 17: Clinical and Commercial Positioning of Crenezumab 194
Figure 18: Clinical and Commercial Positioning of Aducanumab 201
Figure 19: Clinical and Commercial Positioning of Flebogamma + Albutein in AD 207
Figure 20: Clinical and Commercial Positioning of Namzaric 213
Figure 21: Clinical and Commercial Positioning of MK-8931 218
Figure 22: Clinical and Commercial Positioning of AZD-3293 222
Figure 23: Clinical and Commercial Positioning of TTP-488 227
Figure 24: Clinical and Commercial Positioning of TRx-0237 232
Figure 25: Clinical and Commercial Positioning of AB-1010 237
Figure 26: Clinical and Commercial Positioning of AD-4833 242
Figure 27: Clinical and Commercial Positioning of EVP-6124 247
Figure 28: Clinical and Commercial Positioning of LuAE-58054 251
Figure 29: Clinical and Commercial Positioning of ARC-029 256
Figure 30: Company Portfolio Gap Analysis in AD, 2013-2023 261
Figure 31: Actavis SWOT Analysis in AD, 2013-2023 264
Figure 32: Lundbeck SWOT Analysis in AD, 2013-2023 267
Figure 33: Eisai SWOT Analysis in AD, 2013-2023 269
Figure 34: Pfizer SWOT Analysis in AD, 2013-2023 271
Figure 35: Novartis SWOT Analysis in AD, 2013-2023 274
Figure 36: Roche SWOT Analysis in AD, 2013-2023 276
Figure 37: Eli Lilly SWOT Analysis in AD, 2013-2023 279
Figure 38: Merck SWOT Analysis in AD, 2013-2023 281
Figure 39: AstraZeneca SWOT Analysis in AD, 2013-2023 283
Figure 40: Takeda SWOT Analysis in AD, 2013-2023 285
Figure 41: Global Sales for AD by Region, 2013-2023 291
Figure 42: Global Sales for AD by Patient Group, 2013-2023 293
Figure 43: Sales for AD in the US by Drug Class, 2013-2023 300
Figure 44: Sales for AD in France by Drug Class, 2013-2023 307
Figure 45: Sales for AD in Germany by Drug Class, 2013-2023 314
Figure 46: Sales for AD in Italy by Drug Class, 2013-2023 320
Figure 47: Sales for AD in Spain by Drug Class, 2013-2023 326
Figure 48: Sales for AD in the UK by Drug Class, 2013-2023 331
Figure 49: Sales for AD in Japan by Drug Class, 2013-2023 338
Figure 50: Sales for AD in China by Drug Class, 2013-2023 344
Figure 51: Sales for AD in India by Drug Class, 2013?2023 349

Companies Mentioned
Actavis
Lundbeck
Eisai
Pfizer
Novartis
Roche
Eli Lilly
Merck and Co.
AstraZeneca
Takeda

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.